Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone vs. Paroxetine for Panic Attacks
NCT00206765Phase 2Terminated
- Sponsor
- Mount Sinai Beth Israel
- Start
- Jan 2003
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risperidone in panic disorder, major depressive disorder (MDD), sponsored by Mount Sinai Beth Israel. Started Jan 2003; status: terminated.
02
Drugs
risperidone
03
Conditions
panic disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00206765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206765.